Chemed (CHE) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Chemed (CHE) has outperformed GeneDx (WGS) over the past year, gaining 15.0% versus a loss of 43.3%. Over five years, CHE leads with a +16.6% price change compared with -73.3% for WGS. Chemed is the larger company by market cap ($6.49 billion vs $1.96 billion), about 3.3 times the size.
On valuation, Chemed trades at a lower forward P/E (18.1x vs 54.8x for GeneDx). Chemed pays a dividend yielding 0.48%, while GeneDx does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHE | WGS |
|---|---|---|
| Share price | $496.80 | $65.73 |
| Market cap | $6.49B | $1.96B |
| 1-day change | -0.93% | -4.09% |
| YTD return | +17.20% | -47.31% |
| 1-year return | +14.99% | -43.25% |
| 5-year return | +16.58% | -73.34% |
| P/E ratio (TTM) | 24.99 | — |
| Forward P/E | 18.05 | 54.84 |
| EPS (TTM) | $19.88 | $-3.63 |
| Dividend yield | 0.48% | 0.00% |
| Annual dividend | $2.40 | $0.00 |
| Revenue (latest FY) | $2.53B | — |
| Revenue growth (YoY) | +4.06% | — |
| Net income (latest FY) | $265.24M | — |
| Gross margin | 32.54% | — |
| Operating margin | 13.37% | — |
| Net margin | 10.48% | — |
| 52-week high | $557.00 | $170.87 |
| 52-week low | $365.21 | $32.21 |
| Distance from 52-week high | -10.81% | -61.54% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +15.06% | +42.26% |
| Average volume | 159.79K | 728.47K |
| Shares outstanding | 13.07M | 29.82M |
| Employees | 15,811 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Chemed is about 3.3 times larger than GeneDx by market value ($6.49B vs $1.96B).
- CHE has outperformed WGS by 58.2 percentage points over the past year.
About Chemed
CHE stock →Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments.
Health Care · Medical/Nursing Services · 15,811 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
CHE vs WGS FAQ
Which is bigger, Chemed or GeneDx?
Chemed (CHE) is larger, with a market capitalization of $6.49B compared with $1.96B for GeneDx (WGS).
Which stock has performed better over the past year, CHE or WGS?
CHE returned +14.99% over the past 12 months, compared with -43.25% for WGS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Chemed or GeneDx?
Chemed pays a dividend yielding 0.48%, while GeneDx does not currently pay a regular dividend.
Are Chemed and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.